PREX1 and myalgic encephalomeyelitis/chronic fatigue syndrome: Our findings demonstrated for the first time that P-Rex1 was an essential signaling mediator in CFs activation and subsequent cardiac fibrosis, and 1A-116 could be a potential pharmacological development drug.